IL6 and breast cancer: TNBC demonstrates significantly heightened immunogenicity compared to ER-positive/HER2-negative BC, owing to its enriched tumor microenvironment characterized by elevated TILs, pro-inflammatory mediators (e.g. IL-6, CXCL10), and CD8+T cells (18).